Skip to main content

ORIGINAL RESEARCH article

Front. Cardiovasc. Med.
Sec. Structural Interventional Cardiology
Volume 11 - 2024 | doi: 10.3389/fcvm.2024.1424105

Transcatheter Mitral Valve Replacement to Treat Rheumatic Mitral Stenosis: A Case Series

Provisionally accepted
Ping Jin Ping Jin Hong Guo Hong Guo Yu Mao Yu Mao Mengen Zhai Mengen Zhai Yang Liu Yang Liu Jian Yang Jian Yang *
  • Xijing Hospital, Air Force Medical University, Xi’an, Shaanxi Province, China

The final, formatted version of the article will be published soon.

    The studies involving human participants were reviewed and approved by Clinicaltrials Organization: Xijing Hospital, Air Force Medical University.CTA computed tomography angiography DSA digital subtracted angiography MV mitral valve PVL paravalvular leakage RMS rheumatic mitral stenosis TMVR transcatheter mitral valve replacement TTE transthoracic echocardiography ABSTRACT BACKGROUND: Rheumatic mitral stenosis (RMS) is a common valvular heart disease in developing countries. We sought to evaluate the early experience of patients with RMS undergoing transcatheter mitral valve replacement (TMVR).In this retrospective study, a total of 5 RMS patients accepted TMVR. All patients underwent computed tomography and echocardiography before having the procedure. After the preprocedural comprehensive evaluations, the surgeons planned to use the Prizvalve (a novel balloon-expandable transcatheter aortic valve system which is now under the clinical registration study) for TMVR. Clinical data were collected at baseline, before discharge, and at the 30-day follow-up.The median age of the 5 RMS patients was 61 years (range 60-77 years); 60% were male, and the median Society of Thoracic Surgeons score was 13.3% (range 6.2-17.1%). TMVR was successful in all patients. Postoperative transesophageal echocardiography showed that 60.0% (n = 3) of the patients had no paravalvular leakage and 40.0% (n = 2) had trace paravalvular leakage. The median postoperative peak velocity decreased to 1.4 m/s (range 1.1-1.7 m/s), and the median pressure gradient decreased to 3 mmHg (range 2-3 mmHg). No deaths occurred at the 30-day follow-up, and all patients had an improvement of ≥1 on the New York Heart Association functional rating.Our early experience with TMVR in RMS patients suggests that it is a safe and feasible procedure. The early results of the procedure are acceptable and provide bright prospects and directions for the precision treatment of RMS.

    Keywords: Mitral stenosis, Rheumatic valvular heart disease, Transcatheter mitral valve replacement, Prizvalve, Mitral Valve

    Received: 27 Apr 2024; Accepted: 21 Nov 2024.

    Copyright: © 2024 Jin, Guo, Mao, Zhai, Liu and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jian Yang, Xijing Hospital, Air Force Medical University, Xi’an, Shaanxi Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.